Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer

Redox Biology

Volumn 2, Issue 1, 2014, Pages 22-27

  Moser, Justin C ^a   Rawal, Malvika ^a   Wagner, Brett A ^a   Du, Juan ^a   Cullen, Joseph J ^a,b,c   Buettner, Garry R ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Ascorbate; Electron paramagnetic resonance; EPR; Ferritin; Ionizing radiation; Labile iron

Indexed keywords

ASCORBIC ACID; IRON; FERRITIN; FERRIOXAMINE; HYDROGEN PEROXIDE; LABILE IRON; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER RADIOTHERAPY; CELL STRAIN; CELL STRAIN MIA PACA 2; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; TISSUE HOMOGENATE; TISSUE SECTION; ANIMAL; DRUG EFFECTS; MALE; METABOLISM; PANCREATIC NEOPLASMS; PROSTATE; TUMOR CELL LINE; XENOGRAFT; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CELLULAR DISTRIBUTION; DRUG CYTOTOXICITY; DRUG EFFICACY; ELECTRON SPIN RESONANCE; IRON CHELATION; IRON KINETICS; IRON METABOLISM; MOUSE MODEL; OXIDATION; OXIDATION REDUCTION REACTION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; UPREGULATION;

AGOUTI PACA; MURINAE; MUS MUSCULUS;

ANIMALS; ASCORBIC ACID; CELL LINE, TUMOR; FERRITINS; HUMANS; IRON; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROSTATE; RADIATION, IONIZING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84890143824     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.11.005     Document Type: Article

References (39)

1. Qian S.Y., Buettner G.R. Iron and dioxygen chemistry is an important route to initiation of biological free radical oxidations: an electron paramagnetic resonance spin trapping study. Free Radic. Biol. Med. 1999, 26:1447-1456.
2. Petrat F., de Groot H., Sustmann R., Rauen U. The chelatable iron pool in living cells: a methodically defined quantity. Biol. Chem. 2002, 383:489-502.
3. Espósito B.P., Epsztejn S., Breuer W., Cabantchik Z.I. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem. 2002, 304(1):1-18.
4. Ma Y., de Groot H., Liu Z., Hider R.C., Petrat F. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem. J. 2006, 395(1):49-55.
5. Glei M., Latunde-Dada G.O., Klinder A., Becker T.W., Hermann U., Voigt K., Pool-Zobel B.L. Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat. Res. 2002, 519:151-161.
6. Jian J., Yang Q., Dai J., Eckard J., Axelrod D., Smith J., Huang X. Effects of iron deficiency and iron overload on angiogenesis and oxidative stress-a potential dual role for iron in breast cancer. Free Radic. Biol. Med. 2011, 50:841-847.
7. Ibrahim W.H., Habib H.M., Kamal H., Clair D.K., Chow C.K. Mitochondrial superoxide mediates labile iron level: evidence from Mn-SOD-transgenic mice and heterozygous knockout mice and isolated rat liver mitochondria. Free Radic. Biol. Med. 2013, 65:143-149.
8. Epsztejn S., Glickstein H., Picard V., Slotki I.N., Breuer W., Beaumont C., Cabantchik Z.I. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 1999, 94:3593-3603.
9. Breuer W., Epsztejn S., Cabantchik Z.I. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1996, 382(3):304-308.
10. Konijn A.M., Glickstein H., Vaisman B., Meyron-Holtz E.G., Slotki I.N., Cabantchik Z.I. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood 1999, 94:2128-2134.
11. 2. Blood 2000, 95:2960-2966.
12. Vasquez-Vivar J., Kalyanaraman B., Kennedy M.C. Mitochondrial aconitase is a source of hydroxyl radical. An electron spin resonance investigation. J. Biol. Chem. 2000, 275(19):14064-14069.
13. Buettner G.R. Ascorbate autoxidation in the presence of iron and copper chelates. Free Radic. Res. Commun. 1986, 1:349-353.
14. Petering D.H., Byrnes R.W., Antholine W.E. The role of redox-active metals in the mechanism of action of bleomycin. Chem. Biol. Interact. 1990, 73:133-182.
15. Du J., Martin S.M., Levine M., Wagner B.A., Buettner G.R., Wang S.H., Taghiyev A.F., Du C., Knudson C.M., Cullen J.J. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 2010, 16(2):509-520.
16. Espey M.G., Chen P., Chalmers B., Drisko J., Sun A.Y., Levine M., Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic. Biol. Med. 2011, 50(11):1610-1619.
17. Du J., Cullen J.J., Buettner G.R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta-Rev. Cancer 2012, 1826:443-457.
18. Mikirova N.A., Casciari J.J., Hunninghake R.E., Riordan N.H. Intravenous ascorbic acid protocol for cancer patients: scientific rationale, pharmacology, and clinical experience. Funct. Foods Health Dis. 2013, 3(8):344-366.
19. Welsh J.L., Wagner B.A., van 't Erve T.J., Zehr P.S., Berg D.J., Halfdanarson T.R., Yee N.S., Bodeker K.L., Du J., Roberts L.J., Levine M., Buettner G.R., Cullen J.J. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother. Pharmacol. 2013, 71(3):765-775.
20. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R., Shacter E., Levine M. Ascorbic acid at pharmacologic concentrations selectively kills cancer cells: ascorbic acid as a pro-drug for hydrogen peroxide delivery to tissues. Proc. Natl. Acad. Sci. USA 2005, 102:13604-13609.
21. Chen Q., Espey M.G., Sun A.Y., Lee J.H., Krishna M.C., Shacter E., Choyke P.L., Pooput C., Kirk K.L., Buettner G.R., Levine M. Ascorbic acid in pharmacologic concentrations: a pro-drug for selective delivery of ascorbate radical and hydrogen peroxide to extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA 2007, 104:8749-8754.
22. Olney K.E., Du J., van 't Erve T.J., Witmer J.R., Sibenaller Z.A., Wagner B.A., Buettner G.R., Cullen J.J. Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity. Free Radic. Res. 2013, 47(3):154-163.
23. 2 generation. Cancer Res. 2013, 73(16):5232-5241.
24. Buettner G.R., Jurkiewicz B.A. Catalytic metals, ascorbate, and free radicals: combinations to avoid. Radiat. Res. 1996, 145:532-541.
25. Wardman P., Candeias L.P. Fenton chemistry: an introduction. Radiat. Res. 1996, 145(5):523-531.
26. Bienfait H.F., van den Briel M.L. Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen. Biochim. Biophys. Acta. 1980, 631:507-510.
27. Boyer R.F., McCleary C.J. Superoxide ion as a primary reductant in ascorbate-mediated ferritin iron release. Free Radic. Biol. Med. 1987, 3:389-395.
28. Reelfs O., Tyrrell R.M., Pourzand C. Ultraviolet a radiation-induced immediate iron release is a key modulator of the activation of NF-kappaB in human skin fibroblasts. J. Invest. Dermatol. 2004, 122:1440-1447.
29. Robello E., Galatro A., Puntarulo S. Labile iron pool and ferritin content in developing rat brain gamma-irradiated in utero. Neurotoxicology 2009, 30:430-435.
30. Pelle E., Jian J., Declercq L., Dong K., Yang Q., Pourzand C., Maes D., Pernodet N., Yarosh D.B., Huang X. Protection against ultraviolet A-induced oxidative damage in normal human epidermal keratinocytes under post-menopausal conditions by an ultraviolet A-activated caged-iron chelator: a pilot study. Photodermatol. Photoimmunol. Photomed. 2011, 27:231-235.
31. Koch C.J., Biaglow J.E. Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J. Cell Physiol. 1978, 94(3):299-306.
32. Herst P.M., Broadley K.W., Harper J.L., McConnell M.J. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic. Biol. Med. 2012, 52:1486-1493.
33. Shinozaki K., Hosokawa Y., Hazawa M., Kashiwakura I., Okumura K., Kaku T., Nakayama E. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J. Radiat. Res. 2011, 52:229-237.
34. Buettner G.R. In the absence of catalytic metals, ascorbate does not autoxidize at pH 7: ascorbate as a test for catalytic metals. J. Biochem. Biophys. Methods 1988, 16:27-40.
35. Ling G.N., Kolebic T., Damadian R. Low paramagnetic-ion content in cancer cells: its significance in cancer detection by magnetic resonance imaging. Physiol. Chem. Phys. Med. NMR 1990, 22(1):1-14.
36. Baader S.L., Bruchelt G., Carmine T.C., Lode H.N., Rieth A.G., Niethammer D. Ascorbic-acid-mediated iron release from cellular ferritin and its relation to the formation of DNA strand breaks in neuroblastoma cells. J. Cancer Res. Clin. Oncol. 1994, 120(7):415-421.
37. 2-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol. Biochem. 2010, 25(6):767-774.
38. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., Wesley R.A., Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med. 2004, 140(7):533-537.
39. Wagner B.A., Witmer J.R., van 't Erve T.J., Buettner G.R. An assay for the rate of removal of extracellular hydrogen peroxide by cells. Redox Biol. 2013, 1:210-217.